Louise Segan

Louise Segan

Auto-generated profile, based on publicly available information

Louise Segan

The Baker Heart and Diabetes Research Institute, Melbourne, Victoria, Australia; The Alfred Hospital, Melbourne, Victoria, Australia; University of Melbourne, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in JACC: Heart Failure
Verified
Journal Article
Closed access
DCDavid Chieng
David Chieng
HSHariharan Sugumar
Hariharan Sugumar
LSLouise Segan
Louise Segan
CTCaleb Tan
Caleb Tan
DVDonna Vizi
Donna Vizi
LLLiang-Han Ling
Liang-Han Ling

27 September 2022 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
PDF file
DCDavid Chieng
David Chieng
RCRodrigo Canovas
Rodrigo Canovas
LSLouise Segan
Louise Segan
HSHariharan Sugumar
Hariharan Sugumar
AVAleksandr Voskoboinik
Aleksandr Voskoboinik
PKPeter M Kistler
Peter M Kistler
Epidemiological studies report the beneficial effects of habitual coffee consumption on incident arrhythmia, cardiovascular disease (CVD), and mortality. However, the impact of different coffee preparations on cardiovascular outcomes and survival is largely unknown. The aim of this study was to evaluate associations between coffee subtypes on incident outcomes, utilizing the UK Biobank. Coffee subtypes were defined as decaffeinated, ground, and instant, then divided into 0, 5 cups/day, and compared with non-drinkers. Cardiovascular disease included coronary heart disease, cardiac failure, and ischaemic stroke. Cox regression modelling with hazard ratios (HRs) assessed associations with incident arrhythmia, CVD, and mortality. Outcomes were determined through ICD codes and death records. A total of 449 563 participants (median 58 years, 55.3% females) were followed over 12.5 ± 0.7 years. Ground and instant coffee consumption was associated with a significant reduction in arrhythmia at 1–5 cups/day but not for decaffeinated coffee. The lowest risk was 4–5 cups/day for ground coffee [HR 0.83, confidence interval (CI) 0.76–0.91, P < 0.0001] and 2–3 cups/day for instant coffee (HR 0.88, CI 0.85–0.92, P < 0.0001). All coffee subtypes were associated with a reduction in incident CVD (the lowest risk was 2–3 cups/day for decaffeinated, P = 0.0093; ground, P < 0.0001; and instant coffee, P < 0.0001) vs. non-drinkers. All-cause mortality was significantly reduced for all coffee subtypes, with the greatest risk reduction seen with 2–3 cups/day for decaffeinated (HR 0.86, CI 0.81–0.91, P < 0.0001); ground (HR 0.73, CI 0.69–0.78, P < 0.0001); and instant coffee (HR 0.89, CI 0.86–0.93, P < 0.0001). Decaffeinated, ground, and instant coffee, particularly at 2–3 cups/day, were associated with significant reductions in incident CVD and mortality. Ground and instant but not decaffeinated coffee was associated with reduced arrhythmia. Coffee subtypes and associations with incident arrhythmia, CVD, and mortality. Caffeinated (ground/instant) but not decaffeinated coffee reduced the risk of arrhythmia. Both caffeinated and decaffeinated coffee reduced incident CVD and all-cause and cardiovascular mortality risks. CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio.

23 June 2023 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
LSLouise Segan
Louise Segan
RCRodrigo Canovas
Rodrigo Canovas
SNShane Nanayakkara
Shane Nanayakkara
DCDavid Chieng
David Chieng
SPSandeep Prabhu
Sandeep Prabhu
PKPeter M Kistler
Peter M Kistler
Lifestyle risk factors are a modifiable target in atrial fibrillation (AF) management. The relative contribution of individual lifestyle risk factors to AF development has not been described. Development and validation of an AF lifestyle risk score to identify individuals at risk of AF in the general population are the aims of the study. The UK Biobank (UKB) and Framingham Heart Study (FHS) are large prospective cohorts with outcomes measured >10 years. Incident AF was based on International Classification of Diseases version 10 coding. Prior AF was excluded. Cox proportional hazards regression identified independent AF predictors, which were evaluated in a multivariable model. A weighted score was developed in the UKB and externally validated in the FHS. Kaplan–Meier estimates ascertained the risk of AF development. Among 314 280 UKB participants, AF incidence was 5.7%, with median time to AF 7.6 years (interquartile range 4.5–10.2). Hypertension, age, body mass index, male sex, sleep apnoea, smoking, and alcohol were predictive variables (all P < 0.001); physical inactivity [hazard ratio (HR) 1.01, 95% confidence interval (CI) 0.96–1.05, P = 0.80] and diabetes (HR 1.03, 95% CI 0.97–1.09, P = 0·38) were not significant. The HARMS2-AF score had similar predictive performance [area under the curve (AUC) 0.782] to the unweighted model (AUC 0.802) in the UKB. External validation in the FHS (AF incidence 6.0% of 7171 participants) demonstrated an AUC of 0.757 (95% CI 0.735–0.779). A higher HARMS2-AF score (≥5 points) was associated with a heightened AF risk (score 5–9: HR 12.79; score 10–14: HR 38.70). The HARMS2-AF risk model outperformed the Framingham-AF (AUC 0.568) and ARIC (AUC 0.713) risk models (both P < 0.001) and was comparable to the CHARGE-AF risk score (AUC 0.754, P = 0.73). The HARMS2-AF score is a novel lifestyle risk score which may help identify individuals at risk of AF in the general community and assist population screening. HARMS2-AF lifestyle risk score (left). Performance of the HARMS2-AF risk score in predicting the 5- and 10-year risk of AF development among the UKB and FHS (top right). Kaplan–Meier estimate of AF risk according to risk tertiles in the UKB (bottom right). AF, atrial fibrillation; AUC, area under the curve; BMI, body mass index; CI, confidence interval; FHS, Framingham Heart Study; HR, hazard ratio; UKB, UK Biobank.

1 January 2021 in Therapeutic Advances in Reproductive Health
Verified
Journal Article
Open access
PDF file
JGJessica A Grieger
Jessica A Grieger
MHMelinda J. Hutchesson
Melinda J. Hutchesson
SCShamil D. Cooray
Shamil D. Cooray
MKMahnaz Bahri Khomami
Mahnaz Bahri Khomami
SZSarah Zaman
Sarah Zaman
LMLisa Moran
Lisa Moran
The rates of maternal overweight and obesity, but also excess gestational weight gain, are increasing. Pregnancy complications, including gestational diabetes mellitus, gestational hypertension, pre-eclampsia and delivery of a preterm or growth restricted baby, are higher for both women with overweight and obesity and women who gain excess weight during their pregnancy. Other conditions such as polycystic ovary syndrome are also strongly linked to overweight and obesity and worsened pregnancy complications. All of these conditions place women at increased risk for future cardiometabolic diseases. If overweight and obesity, but also excess gestational weight gain, can be reduced in women of reproductive age, then multiple comorbidities associated with pregnancy complications may also be reduced in the years after childbirth. This narrative review highlights the association between maternal overweight and obesity and gestational weight gain, with gestational diabetes, pre-eclampsia, polycystic ovary syndrome and delivery of a preterm or growth restricted baby. This review also addresses how these adverse conditions are linked to cardiometabolic diseases after birth. We report that while the independent associations between obesity and gestational weight gain are evident across many of the adverse conditions assessed, whether body mass index or gestational weight gain is a stronger driving factor for many of these is currently unclear. Mechanisms linking gestational diabetes mellitus, gestational hypertension, pre-eclampsia, preterm delivery and polycystic ovary syndrome to heightened risk for cardiometabolic diseases are multifactorial but relate to cardiovascular and inflammatory pathways that are also found in overweight and obesity. The need for post-partum cardiovascular risk assessment and follow-up care remains overlooked. Such early detection and intervention for women with pregnancy-related complications will significantly attenuate risk for cardiovascular disease.

31 August 2024 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JWJeremy William
Jeremy William
DCDavid Chieng
David Chieng
ACAnnie G Curtin
Annie G Curtin
HSHariharan Sugumar
Hariharan Sugumar
LLLiang Han Ling
Liang Han Ling
PKPeter M Kistler
Peter M Kistler
Background and Aims: Posterior wall isolation (PWI) is commonly incorporated into catheter ablation (CA) strategies for persistent atrial fibrillation (AF) in an attempt to improve outcomes. In the CAPLA randomized study, adjunctive PWI did not improve freedom from atrial arrhythmia at 12 months compared with pulmonary vein isolation (PVI) alone. Whether additional PWI reduces arrhythmia recurrence over the longer term remains unknown. Methods: In this multi-centre, international, randomized study patients with persistent AF undergoing index CA using radiofrequency were randomized to PVI + PWI vs. PVI alone. Patients underwent regular follow-up including rhythm monitoring for a minimum of 3 years after CA. Atrial fibrillation burden at 3 years after ablation was evaluated with either 28-day continuous ambulatory electrocardiogram (ECG) monitoring, twice daily single-lead ECG or from cardiac implanted device. Evaluated endpoints included freedom from any documented atrial arrhythmia recurrence after a single procedure, AF burden, need for redo CA, rhythm at last clinical follow-up, healthcare utilization metrics, and AF-related quality of life. Results: Three hundred thirty-three of 338 (98.5%) patients (mean age 64.3 ± 9.4 years, 23% female) completed 3-year follow-up, with 169 patients randomized to PVI + PWI and 164 patients to PVI alone. At a median of 3.62 years after index ablation, freedom from recurrent atrial arrhythmia occurred in 59 patients (35.5%) randomized to PVI + PWI vs. 68 patients (42.1%) randomized to PVI alone (hazard ratio 1.15, 95% confidence interval 0.88–1.51, P = .55). Median time to recurrent atrial arrhythmia was 0.53 years (interquartile range 0.34–1.01 years). Redo ablation was performed in 54 patients (32.0%) in the PVI + PWI group vs. 49 patients (29.9%, P = .68) in the PVI alone group. Pulmonary vein reconnection was present in 54.5% (mean number of reconnected PVs 2.2 ± .9) and posterior wall reconnection in 75%. Median AF burden at 3 years was 0% in both groups (interquartile range 0%–0.85% PVI + PWI vs. 0%–1.43% PVI alone, P = .49). Sinus rhythm at final clinical follow-up was present in 85.1% with PVI + PWI vs. 87.1% with PVI alone (P = .60). Mean AF Effect On Quality-Of-Life (AFEQT) score at 3 years after ablation was 88.0 ± 14.8 with PVI + PWI vs. 88.9 ± 15.4 with PVI alone (P = .63). Conclusions: In patients with persistent AF, the addition of PWI to PVI alone at index radiofrequency CA did not significantly improve freedom from atrial arrhythmia recurrence at long-term follow-up. Median AF burden remains low and AF quality of life high at 3 years with either ablation strategy.

25 August 2023 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
LSLouise Segan
Louise Segan
DCDavid Chieng
David Chieng
SPSandeep Prabhu
Sandeep Prabhu
AHAndrew Hunt
Andrew Hunt
TWTroy Watts
Troy Watts
PKPeter M. Kistler
Peter M. Kistler